SCHEMBL4354004

SCHEMBL4354004

Cc1ccc(-n2cc(C(=O)O)c(=O)[nH]2)cc1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALKBH5 Q6P6C2 3/20 0.51
NPSR1 Q6W5P4 2/20 0.43
HPGD P15428 2/20 0.43
HSD17B10 Q99714 2/20 0.43
POLB P06746 1/20 0.43
MPL P40238 1/20 0.41
STAT1 P42224 1/20 0.40
MCL1 Q07820 2/20 0.40
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
GAA P10253 1/20 0.39
DUSP3 P51452 2/20 0.39
MYC P01106 2/20 0.39
CTSB P07858 2/20 0.39
KLKB1 P03952 1/20 0.39
ELANE P08246 1/20 0.39
MMP9 P14780 1/20 0.39
PKM P14618 1/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11003364 0.83 HPGD (0.46) ALKBH5NPSR1HPGDHSD17B10POLB
SCHEMBL11002564 0.78 ESR1 (0.43) NPSR1HPGDHSD17B10POLBALDH1A1
SCHEMBL11000015 0.77 KDM4E (0.45) NPSR1HPGDHSD17B10POLBALDH1A1
SCHEMBL11156275 0.76 HPGD (0.58) ALKBH5NPSR1HPGDHSD17B10POLB
SCHEMBL10921947 0.76 POLB (0.39) NPSR1HPGDHSD17B10POLBMCL1
SCHEMBL10998243 0.76 KDM4E (0.48) NPSR1HPGDHSD17B10POLBMCL1
SCHEMBL10922417 0.75 MCL1 (0.40) ALKBH5NPSR1HPGDHSD17B10POLB
SCHEMBL10924857 0.74 SCN2A (0.48) HPGDHSD17B10POLBALDH1A1KDM4E
SCHEMBL10999707 0.72 TDP1 (0.45) POLBALDH1A1GAAPKMKMT2A
SCHEMBL10920350 0.71 ALDH1A1 (0.43) NPSR1HPGDHSD17B10POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
CN-101343251-B Thrombopoietin mimetics SMITHKLINE BEECHAM CORP 2011-11-09 CN disclosed
CN-101343250-B Thrombopoietin mimetics SMITHKLINE BEECHAM CORP 2011-09-21 CN disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
CN-101343251-A Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-01-14 CN disclosed
CN-101343250-A Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-01-14 CN disclosed
CN-101342169-A Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-01-14 CN disclosed
CN-100423721-C Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2008-10-08 CN disclosed
EP-1889838-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2008-02-20 EP disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK ALKBH5 3890/4885NPSR1 508/4885HPGD 1200/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK ALKBH5 3890/4885NPSR1 508/4885HPGD 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.